Pipeline

English

Program Indication Program Stage Commercial Rights
 
Lanifibranor
  • Nonalcoholic steatohepatitis (NASH)
  • Phase IIb
Inventiva
Lanifibranor
  • Systemic Sclerosis (SSc)
  • Phase IIb
 Inventiva
Odiparcil
  • Mucopolysaccharidosis type VI (MPS VI)
  • Phase IIa (in preparation)
 Inventiva
ROR-γ
  • Moderate to severe psoriasis
  • Preclinic
abbvie 
(Sales royalties for Inventiva)
YAP/TEAD
  • Malignant Mesothelioma, Lung Cancer
  • Discovery
 Inventiva
NSD2
  • Multiple Myeloma
  • Discovery
 Inventiva
EPICURE
  • Immuno-oncology
  • Research
Inventiva
Undisclosed target
  • Idiopathic Pulmonary Fibrosis (IPF)
  • Discovery
 
(Sales royalties for Inventiva)